Androgen Receptor and ETS-Like Protein-1 Expression of Prostate Cancer Correlates with Gleason Score International Society of Urological Pathology 2014/WHO 2016
DOI:
https://doi.org/10.3889/oamjms.2021.5895Keywords:
Androgen receptor, ETS-like protein1, Gleason score, Prostate cancerAbstract
AIM: Prostate cancer is the second most common and the fifth leading cause of death by cancer in men worldwide now. Grading based on Gleason score is a significant prognostic factor of prostate cancer. Androgen receptor (AR) plays important role in the initiation and progression of prostate cancer. AR signaling pathways in prostate cancer can also promote MAPK/ERK signaling pathways which activate ETS-like protein1 (Elk-1).
METHODS: A total of 56 slides and paraffin blocks sampling of prostate cancer by consecutive from Department of Anatomical Pathology in West Sumatera. Hematoxylin and eosin (HE) stained slides were evaluated to review Gleason score, histopathological grading, and WHO grade group based on International Society of Urological Pathology (ISUP) 2014/WHO 2016. Immunohistochemistry staining of AR and Elk-1 was performed to analyze protein expression.
RESULTS: Prostate cancers were found in mean age 70.68 ± 7.99 years. The most proportion of prostate cancer was Gleason score 9 (44.64%), histopathological grading poorly differentiated/undifferentiated (76.78%), and WHO grade Group 5 (48.21%). The positive expression AR of tumor cells 39 (69.64%) and Elk-1 34 (60.71%). Statistically, these results showed significant correlations of AR (p = 0.009) and Elk-1 (p = 0.012) with Gleason score.
CONCLUSIONS: These results showed complex interactions between AR and Elk-1 initiation and progression of prostate cancer. Both variables indicated a significant correlation with Gleason score so that biomarkers prognostic potentially for prostate cancer.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
National Cancer Management Committee, Health Ministry of Indonesia. National Guidelines for Prostate Cancer Medical Services. Jakarta: National Cancer Management Committee; 2017. p. 1-13.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistic 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492 PMid:30207593
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Source, method and major pattern in GLOBOCAN 2012. Int J Cancer. 2015;136(5):359-86. https://doi.org/10.1002/ijc.29210 PMid:25220842
Cancer Registration Agency of the Indonesian Pathology Association. Directorate General of Medical Services Health Ministry of Indonesia. Cancer in Indonesia 2014 Histopathology Data. Jakarta: Cancer Registration Agency of the Indonesian Pathology Association; 2018.
Felgueiras J, Silva JV, Fardilha M. Prostate cancer: The need for biomarkers and new therapeutic targets. J Zheijiang Univ Sci B. 2014;15(1):16-42. https://doi.org/10.1631/jzus.b1300106 PMid:24390742
Ferraldeschi R, Welti J, Luo J, Attard G, Bono JS. Targeting the androgen receptor pathway in castration-resistant prostate cancer: Progresses and prospect. Oncogene. 2015;34()14:1745-57. https://doi.org/10.1038/onc.2014.115 PMid:24837363
Sun Y, Liu WZ, Liu T, Feng X, Yang N, Zhou HF. Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res. 2015;35(6):600-4. https://doi.org/10.3109/10799893.2015.1030412 PMid:26096166
Casalvieri KA, Matheson CJ, Bacos DS, Reigan P. Selective targeting of RSK isoform in cancer. Trends Cancer. 2017;3(4):302-12. https://doi.org/10.1016/j.trecan.2017.03.004 PMid:28718440
Leung Jk, Sadar MD. Non-genomic actions of the androgen receptor in prostate cancer. Front Endocrinol. 2017;8:1-8. https://doi.org/10.3389/fendo.2017.00002 PMid:28144231
Epstein JI, Egevad LL, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. AM J Surg Pathol. 2016;40(2):244-52. https://doi.org/10.1097/pas.0000000000000530 PMid:26492179
Humphrey PA, Epstein JI, Netto GJ, Amin MB, Egevad L, Rubin MA, et al. Acinar adenocarcinoma. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE, editors. WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th ed. Lyon: IARC Press; 2016. p. 138-61.
Shah RB, Zhou M. Recent advances in prostate cancer pathology: Gleason grading and beyond. Pathol Int. 2016;66(5):260-72. https://doi.org/10.1111/pin.1239 PMid:26991008
Williams EM, Higgins JP, Sangoi AR, McKenney JK, Troxell ML. Androgen receptor immunohistochemistry in genitourinary neoplasm. Int Urol Nephrol. 2015;47(1):81-5. https://doi.org/10.1007/s11255-014-0834-7 PMid:25218615
Hashmi AA, Mudassir G, Irfan M, Hussain ZF, Hashmi SK, Asif H, et al. Prognostic significance of high androgen receptor expression in prostatic acinar adenocarcinoma. Asian Pac J Cancer Prev. 2019;20(3):893-6. https://doi.org/10.31557/apjcp.2019.20.3.893 PMid:30912411
Lekshmy KS, Prema NS. Study of various prognostic factors in prostate cancer and its correlation with androgen receptor expression. J Evolution Med Dent Sci. 2019;8(34):2687-93.
Park SW, Kim JH, Lee HJ, Shin DH, Lee SD, Yoon S. The expression of androgen receptor and its variants in human prostate cancer tissue according to disease status, and its prognostic significance. World J Mens Health. 2019;37(1):68-77. https://doi.org/10.5534/wjmh.180003 PMid:29756415
Chen Y, Lin Y, Nie P, Jiang W, Liu Y, Yuan R, et al. Association of prostate-specific antigen, prostate carcinoma tissue Gleason score, and androgen receptor expression with bone metastasis in patients with prostate carcinoma. Med Sci Monit. 2017;23:1768-74. https://doi.org/10.12659/msm.900977 PMid:28400549
Husain I, Shukla S, Soni P, Husain N. Role of androgen receptor in prostatic neoplasia versus hyperplasia. J Can Res Ther. 2016;12(1):112-6. https://doi.org/10.4103/0973-1482.151429 PMid:27072221
Diallo JS, Aldejmah A, Mouhim AF, Fahmy MA, Koumakpayi IH, Sircar K, et al. Co-assesment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implication for prostate cancer development and prognosis. BJU Int. 2008;101(10):1302-9. https://doi.org/10.1111/j.1464-410x.2008.07514.x PMid:18294307
Kawahara T, Aljarah AK, Shareef HK, Inoue S, Ide H, Patterson JD, et al. Silodosin inhibits prostate cancer cell growth via Elk-1 inactivation and enhances the cytotoxic activity of gemcitabine. Prostate. 2016;76(8):744-56. https://doi.org/10.1002/pros.23164 PMid:26864615
Sizemore GM, Pitarresi JR, Balakrishnan S, Ostrowski MC. The ETS family of oncogenic transcription factors in solid tumours. Cancer. 2017;17(6):337-351. https://doi.org/10.1038/nrc.2017.20 PMid:28450705
Patki M, Chari V, Sivakumaran S, Gonit M, Trumbly R, Ratnam M. The ETS domain transcription factor Elk1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells. J Biol Chem. 2013;288(16):11047-65. https://doi.org/10.1074/jbc.m112.438473 PMid:23426362
Hsing M, Wang Y, Rennie PS, Cox ME, Cherkasov A. ETS transcription factors as emerging drug targets in cancer. Med Res Rev. 2019;31(42):1904209. https://doi.org/10.1002/med.21575
Pardy L, Rosati R, Soave C, Huang Y, Kim S, Ratnam M. The ternary complex factor protein Elk1 is an independent prognosticator of disease recurrence in prostate cancer. Prostate. 2020;80(2):198-208. https://doi.org/10.1002/pros.23932 PMid:31794091
Downloads
Published
How to Cite
License
Copyright (c) 2021 Anandia Putriyuni, Djong Tjong, Yanwirasti Yanwirasti, Ariana Alvarino, Tofrizal Tofrizal (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
